Tu, M.M.; Clemons, M.; Stober, C.; Jeong, A.; Vandermeer, L.; Mates, M.; Blanchette, P.; Joy, A.A.; Aseyev, O.; Pond, G.;
et al. Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer. Curr. Oncol. 2021, 28, 1847-1856.
https://doi.org/10.3390/curroncol28030171
AMA Style
Tu MM, Clemons M, Stober C, Jeong A, Vandermeer L, Mates M, Blanchette P, Joy AA, Aseyev O, Pond G,
et al. Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer. Current Oncology. 2021; 28(3):1847-1856.
https://doi.org/10.3390/curroncol28030171
Chicago/Turabian Style
Tu, Megan M., Mark Clemons, Carol Stober, Ahwon Jeong, Lisa Vandermeer, Mihaela Mates, Phillip Blanchette, Anil Abraham Joy, Olexiy Aseyev, Gregory Pond,
and et al. 2021. "Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer" Current Oncology 28, no. 3: 1847-1856.
https://doi.org/10.3390/curroncol28030171
APA Style
Tu, M. M., Clemons, M., Stober, C., Jeong, A., Vandermeer, L., Mates, M., Blanchette, P., Joy, A. A., Aseyev, O., Pond, G., Fergusson, D., Ng, T. L., & Thavorn, K.
(2021). Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer. Current Oncology, 28(3), 1847-1856.
https://doi.org/10.3390/curroncol28030171
